Abstract
Aim: Cabergoline is related to an elevated risk of fibrotic adverse reactions including cardiac valvular and pleuropulmonary fibrosis. We investigated pulmonary and cardiac valve fibrosis and immunological markers before and after 3 and 12 months of treatment with cabergoline in women with prolactinoma.
Material-Methods: The study included thirty-two women with newly diagnosed prolactinoma and 28 healthy women. CAB cumulative dose was 7.8±5.5 mg after 3-month therapy, and 31±22 mg after 12-month follow-up. The risk of autoimmune adverse fibrotic reactions related to CAB treatment including cardiac valvulopathy and pulmonary fibrosis were assessed by a transthoracic echocardiography and pulmonary function tests, respectively. Immunological markers including Antistreptolysin O, Rheumatoid factor, Immunglobuline E, Antinuchlear antibody were also evaluated.
Results: Before the start of CAB therapy, the total prevalence of trace grade of mitral, aortic, pulmonic, and tricuspid valve regurgitations were found as 34%, 3%, 6.3%, and 39 % respectively in women with prolactinoma. After improving of prolactin levels with CAB treatment, no change was found in the prevalence of the all valve regurgitations. There was no deterioration in pulmonary function tests. Rheumatoid factor was found higher in newly diagnosed women with prolactinoma than in healthy women (p=0.01), and this was improved by CAB therapy (p=0.005).
Conclusion: The prospective study indicated that sufficient cabergoline doses for a period of one year treatment of prolactinoma were not found to be related to fibrotic adverse reactions including cardiac valvular and pulmonary fibrosis or increased levels of immunological marker, apart from rheumatoid factor. For the first time Rf was found higher in newly diagnosed women with prolactinoma and was improved after cabergoline therapy.
Keywords: Autoimmune adverse fibrotic reactions, Cabergoline treatment, prolactinoma.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Volume: 16 Issue: 1
Author(s): Berçem Ayçiçek Doğan, Ayse Arduc, Mazhar Müslüm Tuna, Dilek Berker, Nilgün Demirci, Semra Demirtaş, Hülya Çiçekcioğlu and Serdar Güler
Affiliation:
Keywords: Autoimmune adverse fibrotic reactions, Cabergoline treatment, prolactinoma.
Abstract: Aim: Cabergoline is related to an elevated risk of fibrotic adverse reactions including cardiac valvular and pleuropulmonary fibrosis. We investigated pulmonary and cardiac valve fibrosis and immunological markers before and after 3 and 12 months of treatment with cabergoline in women with prolactinoma.
Material-Methods: The study included thirty-two women with newly diagnosed prolactinoma and 28 healthy women. CAB cumulative dose was 7.8±5.5 mg after 3-month therapy, and 31±22 mg after 12-month follow-up. The risk of autoimmune adverse fibrotic reactions related to CAB treatment including cardiac valvulopathy and pulmonary fibrosis were assessed by a transthoracic echocardiography and pulmonary function tests, respectively. Immunological markers including Antistreptolysin O, Rheumatoid factor, Immunglobuline E, Antinuchlear antibody were also evaluated.
Results: Before the start of CAB therapy, the total prevalence of trace grade of mitral, aortic, pulmonic, and tricuspid valve regurgitations were found as 34%, 3%, 6.3%, and 39 % respectively in women with prolactinoma. After improving of prolactin levels with CAB treatment, no change was found in the prevalence of the all valve regurgitations. There was no deterioration in pulmonary function tests. Rheumatoid factor was found higher in newly diagnosed women with prolactinoma than in healthy women (p=0.01), and this was improved by CAB therapy (p=0.005).
Conclusion: The prospective study indicated that sufficient cabergoline doses for a period of one year treatment of prolactinoma were not found to be related to fibrotic adverse reactions including cardiac valvular and pulmonary fibrosis or increased levels of immunological marker, apart from rheumatoid factor. For the first time Rf was found higher in newly diagnosed women with prolactinoma and was improved after cabergoline therapy.
Export Options
About this article
Cite this article as:
Ayçiçek Doğan Berçem, Arduc Ayse, Müslüm Tuna Mazhar, Berker Dilek, Demirci Nilgün, Demirtaş Semra, Çiçekcioğlu Hülya and Güler Serdar, Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma, Endocrine, Metabolic & Immune Disorders - Drug Targets 2016; 16 (1) . https://dx.doi.org/10.2174/1871530316666160229120142
DOI https://dx.doi.org/10.2174/1871530316666160229120142 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
Call for Papers in Thematic Issues
Advancing Therapies for Bone and Joint Diseases: Insights from Natural Products and Herbal Medicines
The aging global population is experiencing an increased risk of bone and joint health issues, notably osteoporosis and osteoarthritis, affecting over half of individuals over 60. Plant-based natural products and herbal medicines are gaining recognition as alternative therapies for these conditions, with secondary metabolites, including flavonoids, coumarins, and others, playing ...read more
Association between Diabetes Mellitus and natural product complementary applications: State of the arts
Diabetes Mellitus (DM) represents a significant global health challenge, characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The increasing prevalence of DM, alongside its associated complications, has prompted researchers and healthcare professionals to explore a variety of management strategies beyond conventional pharmacotherapy. Among these ...read more
Chronic inflammation and Disorders/Cancers
Chronic inflammation is fundamental cause of variety of disorders. Many lifestyle-related diseases including metabolic syndrome, obesity, impairment of immune responses, sepsis, mental illness, and other disorders are caused by chronic inflammation. Prevention of chronic inflammation is related to antiaging effects of our body. Proinflammatory cytokines such as TNF-α is associated ...read more
Immune defense of the blood-tissue barriers which are related to drugs, metabolic and hormones
We have already known that testis is an immune privilege area for the maintenance of spermatogenesis against to any pathogen from the interstitial area. With the BTB integrity there is a qualified selection for the mature sperm until the lumen migration which is sperm release progress. Spermiogenesis help for the ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of 18F-FDG-PET/CT in Infectious Endocarditis and Cardiac Device Infection
Current Molecular Imaging (Discontinued) <i>In Silico</i> Studies for Bacterystic Evaluation against <i>Staphylococcus aureus</i> of 2-Naphthoic Acid Analogues
Current Topics in Medicinal Chemistry Epidemiological Review of Gonococcal Infection
Current Women`s Health Reviews Nano-zinc Coordination with the Ligands of Carboplatin, Oxaliplatin and Nedaplatin. Synthesis, Characterization and Biological Properties
Letters in Organic Chemistry Multiple Roles of Biosurfactants in Biofilms
Current Pharmaceutical Design Editorial (Thematic Issue: From Nuisance to State-of-the-Art: FDG-PET/CT Imaging of Infection and Inflammation)
Current Molecular Imaging (Discontinued) Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant Glioma
Current Gene Therapy Targeting Molecular Imaging Approach for Detection of Infection and Inflammation by Diagnostic Nuclear Medicine Techniques
Current Medical Imaging Hybrid Viral Vectors for Vaccine and Antibody Production in Plants
Current Pharmaceutical Design Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology The Human Microbiome Project, Personalized Medicine and the Birth of Pharmacomicrobiomics
Current Pharmacogenomics and Personalized Medicine Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives
Current Drug Targets The Pathophysiology of Sleep Apnoea: What We have Learned from Animal Models of Chronic Intermittent Hypoxia
Current Respiratory Medicine Reviews Injecting Illicit Substances Epidemic and Infective Endocarditis
Infectious Disorders - Drug Targets Black Fungus: An Alarming Infection During Novel Coronavirus: A Review
Anti-Infective Agents Cefixime-induced Oromandibular Dystonia in an Adult: A Case Report
Current Drug Safety Older Adults Prescribed Methadone: A Review of the Literature Across the Life Span from Opiate Initiation to Methadone Maintenance Treatment
Current Drug Abuse Reviews Clopidogrel and Aspirin in Cardiovascular Medicine: Responders or Not -- Current Best Available Evidence
Cardiovascular & Hematological Agents in Medicinal Chemistry Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke
Current Drug Targets - CNS & Neurological Disorders Indications for Heart Transplantation in Congenital Heart Disease
Current Cardiology Reviews